Company Overview
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.
Why Investors Should Care
Revenue has grown at a 99.2% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $85.23M (+129.1% YoY); net profit $2.70M.
- Trailing 12 Months Year-on-year growth — revenue +20.6%, earnings +0.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 99.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 99.23% |
| 1 Year: | 20.60% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | 0.00% |
Stock Price Performance
| 1 Year: | +48.33% |
| 6 Months: | +81.50% |
| 3 Months: | +54.45% |
| 1 Month: | +6.53% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)59.17 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 99.2% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DCTH Delcath Systems, Inc. R2KPHARMA | 16.48 | - | $568.92M | 0.00% | 0.59% | 0.47% | 99.23% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | 584.00K | 684.00K | - | - | 858.00K | 824.00K | - | - | - | - | - | - | - | - | - | 378.00K | 797.00K | 906.00K | 597.00K | 495.00K | 434.00K | 3.14M | 7.77M | 11.20M | 19.78M | 24.16M | 20.56M | 24.99M | 29.13M |
| Gross Profit | 167.00K | - | 311.00K | 329.00K | 309.00K | - | 259.00K | 361.00K | 323.00K | - | 524.00K | 449.00K | 512.00K | - | 555.00K | 638.00K | 591.00K | 174.00K | 240.00K | 208.00K | 216.00K | 211.00K | 278.00K | 276.00K | 334.00K | 295.00K | 345.00K | 617.00K | 671.00K | 416.00K | 345.00K | 301.00K | 2.24M | 6.25M | 9.56M | 16.94M | 20.84M | 17.94M | 21.26M | 26.15M |
| Operating Income | -5.05M | -3.29M | -3.71M | -3.62M | -3.65M | -4.23M | -3.46M | -3.87M | -4.72M | -4.38M | -4.21M | -4.60M | -4.63M | -4.72M | -7.50M | -6.09M | -5.79M | -5.67M | -4.13M | -5.57M | -5.07M | -4.27M | -4.98M | -6.73M | -6.45M | -6.70M | -8.34M | -9.49M | -8.17M | -8.32M | -8.00M | -10.56M | -10.28M | -3.91M | -1.26M | 642.00K | 2.59M | -388.00K | -1.64M | 2.40M |
| Net Income | -4.56M | -2.94M | -3.49M | -3.70M | -2.42M | -5.09M | -1.81M | -6.67M | -1.00M | -8.49M | -11.33M | -1.94M | -12.60M | -19.25M | 7.18M | -6.66M | -8.88M | -7.89M | -5.96M | -7.52M | -7.86M | -4.28M | -4.99M | -6.75M | -6.43M | -7.12M | -9.00M | -10.16M | -8.88M | -9.00M | -7.20M | -20.34M | -11.11M | -13.74M | 1.86M | 1.07M | 2.70M | 830.00K | -1.07M | 2.67M |
| Diluted EPS | -0.48 | -0.31 | - | -0.30 | - | - | - | -4.41 | - | - | -45,695.00 | -1,373.00 | -4,565.00 | - | 10.91 | -7.26 | -0.25 | -75.11 | -58.50 | -73.82 | -108.07 | -1.90 | -1.16 | -1.04 | -0.96 | -0.94 | -1.10 | -1.24 | -0.96 | -0.77 | -0.58 | -1.14 | -0.45 | -0.48 | 0.06 | 0.03 | 0.07 | 0.02 | -0.03 | 0.07 |
| R&D Expense | 683.00K | - | 979.00K | 1.45M | 1.68M | - | 1.34M | 1.95M | 2.69M | - | 2.32M | 2.52M | 2.28M | - | 5.69M | 4.09M | 4.11M | 3.30M | 1.71M | 1.78M | 2.97M | 2.22M | 3.26M | 3.71M | 3.50M | 2.96M | 4.48M | 5.61M | 4.07M | 4.58M | 3.56M | 4.66M | 3.70M | 3.39M | 3.87M | 5.01M | 6.88M | 7.99M | 9.82M | 10.38M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 346.00K | 790.00K | 1.07M | 1.75M | 1.99M | 2.71M | - | - | - | 3.56M | 2.72M | 2.06M | 37.20M | 85.23M |
| Gross Profit | - | 0 | 0 | 307.00K | 326.00K | 778.00K | 1.28M | 1.44M | 2.01M | 2.40M | 861.00K | 1.01M | 2.88M | 2.03M | 1.43M | 31.02M | 73.43M |
| Operating Income | -13.54M | -30.74M | -46.46M | -53.87M | -33.02M | -19.30M | -15.21M | -16.44M | -18.16M | -27.07M | -19.91M | -21.30M | -24.53M | -33.85M | -38.18M | -12.41M | 660.00K |
| Net Income | -22.06M | -46.68M | -30.89M | -51.87M | -30.32M | -17.38M | -14.70M | -17.97M | -45.12M | -19.22M | -8.88M | -24.16M | -25.65M | -36.51M | -47.68M | -26.39M | 2.70M |
| Diluted EPS | - | - | -0.68 | -13.54 | -5.10 | -1.84 | -0.91 | - | -3,250.00 | -0.72 | -342.83 | -8.35 | -3.59 | -4.12 | -2.94 | -0.93 | 0.07 |
| R&D Expense | 9.64M | 17.56M | 25.17M | 26.21M | 12.69M | 4.30M | 6.49M | 8.45M | 10.49M | 19.65M | 9.49M | 11.20M | 13.78M | 18.58M | 17.50M | 13.87M | 29.25M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Aug 1988 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | 50.58M | 35.24M | 30.47M | 37.10M | 23.76M | 15.73M | 35.24M | 8.89M | 6.84M | 14.21M | 34.63M | 33.12M | 17.86M | 38.61M | 76.59M | 123.63M |
| Total Equity | 0 | 10.21M | 23.76M | 29.08M | 26.10M | 20.01M | 30.10M | 18.14M | 8.60M | -1.49M | 678.00K | -14.94M | -6.36M | 22.08M | 11.95M | -5.86M | 15.78M | 68.75M | 111.22M |
| Cash & Equivalents | 0 | 6.94M | 35.49M | 45.62M | 25.78M | 23.73M | 31.25M | 20.47M | 12.61M | 4.41M | 4.00M | 2.52M | 10.00M | 28.57M | 22.80M | 7.67M | 12.65M | 32.41M | 43.45M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 15.69M | 10.15M | 0 | - |
| Total Liabilities | - | - | - | - | - | - | - | 5.62M | 7.13M | 36.73M | 8.21M | 21.78M | 20.57M | 12.56M | 21.17M | 23.72M | 22.84M | 7.84M | 12.41M |
| Current Liabilities | - | - | - | 21.20M | 8.84M | 10.16M | 6.63M | 4.58M | 6.31M | 36.09M | 7.81M | 17.75M | 15.99M | 10.04M | 5.95M | 14.73M | 16.45M | 6.14M | 10.95M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -10.46M | -24.08M | -37.37M | -50.01M | -34.10M | - | - | - | -15.40M | -14.73M | -23.69M | -22.87M | -22.60M | -24.95M | -31.25M | -18.68M | 22.52M |
| Investing Cash Flow | 3.53M | -3.13M | -6.09M | 2.86M | -142.00K | - | - | - | -524.00K | -76.00K | -24.00K | -782.00K | -143.00K | -209.00K | -19.71M | -981.00K | -26.59M |
| Financing Cash Flow | 35.48M | 37.35M | 23.62M | 45.06M | 41.70M | - | - | - | -10.52M | 13.24M | 30.30M | 42.35M | 20.82M | 10.14M | 51.78M | 39.41M | 15.05M |
| Capital Expenditure | -515.00K | -1.64M | -2.61M | -2.12M | -142.00K | -44.00K | -170.00K | -258.00K | -524.00K | -76.00K | -24.00K | -782.00K | -143.00K | -209.00K | -58.00K | -559.00K | -1.55M |
| Free Cash Flow | -10.98M | -25.72M | -39.98M | -52.13M | -34.24M | - | - | - | -15.92M | -14.81M | -23.71M | -23.65M | -22.75M | -25.16M | -31.31M | -19.24M | 20.97M |
| Share Buybacks | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 6.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | 88.7% | 41.3% | 72.8% | 73.6% | 72.4% | 74.2% | - | - | - | 81.1% | 74.8% | 69.2% | 83.4% | 86.2% |
| Operating Margin % | - | - | - | -15,569.7% | -4,179.6% | -1,805.8% | -870.6% | -825.3% | -669.1% | - | - | - | -690.0% | -1,245.1% | -1,849.0% | -33.4% | 0.8% |
| Net Margin % | - | - | - | -14,990.8% | -3,838.5% | -1,625.9% | -841.7% | -902.2% | -1,661.8% | - | - | - | -721.5% | -1,342.7% | -2,308.9% | -70.9% | 3.2% |
| ROE % | -92.8% | -160.5% | -118.3% | -259.2% | -100.7% | -95.8% | -171.0% | 1,206.1% | -6,654.4% | 128.7% | 139.7% | -109.4% | -214.6% | 623.1% | -302.2% | -38.4% | 2.4% |
| ROCE % | - | -104.6% | -175.9% | -265.1% | -108.4% | -100.6% | -161.4% | 1,920.6% | -1,692.9% | 248.2% | 1,117.2% | -86.6% | -90.3% | -1,082.6% | -172.3% | -17.6% | 0.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | - | 2.71M | $44.23M |
| 2 | State Street Corporation | - | 679.28K | $11.10M |
| 3 | Geode Capital Management, LLC | - | 733.12K | $11.98M |
| 4 | Vanguard Capital Management LLC | - | 1.22M | $19.96M |
| 5 | Propel Bio Management, LLC | - | 871.46K | $14.24M |
| 6 | Algert Global, LLC | - | 580.71K | $9.49M |
| 7 | Rosalind Advisors, Inc. | - | 3.30M | $53.93M |
| 8 | Millennium Management Llc | - | 566.37K | $9.25M |
| 9 | Divisadero Street Capital Management, LP | - | 499.80K | $8.17M |
| 10 | Morgan Stanley | - | 407.98K | $6.67M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DCTH
What Makes Delcath Systems, Inc. (DCTH) a Strong Momentum Stock: Buy Now? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxQVkJUVlpHVGQ5aTJ2RjR3eGJxQ0Z4ckpHelBMeVJuNks3RDV4MGU5T2JsdUEzSC0zNTJqX1JqS0UzS3Nnd2oxWnRsNHJjekp3cEtEZHlWTXI0cU9KQmNTYjQtcF9mTk9Pd1RERk9rWk1ERUJsVlViZDVXTTRaa3R0T21OWmpJREdkeUxzTX…
Delcath Systems will attend two investor conferences in September - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxQWjFoYTU1Y2x0bFJfcmFod3kzYWlQWWE2QmxOMWFqR09yc1dITmhQQjVUekV0akd3RnRNa0RnZTBaclh6Q01SQnV0aFNscWFxVDdiRUJZTDE3aEd6RHF0T0J0UENqWFhHVzNWVDNFdDM0ZTNIYjh6TXhIWkllMXRCY3dWOTM5am9vdWhmdH…
How (DCTH) Movements Inform Risk Allocation Models - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxQamdrMWFZREJZTVN3c2l2MDZmVEpyNkVjTl9aQVJKMzVpQlZaeVdXWkJKS09NUDMtbEROYzhtMTVjclE0eW5YT0RmajI5MDBKNlg2c0djcUJja1czZEN6UGlkWHRlWGN6QTJ0QjVWWE9CY2tUYTdudXJNRUhfeUJhSjRST29kU2VPVFlud0…
DCTH Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9KUXNHdUhqcnpMZk5aa0tTb2wxYXJtbkE4N0xoOTVHdm9wR0RzQk9IakEtdFhHT3VtbUVSMlQ3N1N4U2ltREEzYVBySE45UlQ3TGVnbXR3Zlg2YURfVXpWM1RIdUdwa3pnSTBmR1lqOFc3Xy1KSjU0eHN3?oc=5" target="_blank">DCT…
DELCATH SYSTEMS ($DCTH) Releases Q4 2025 Earnings - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxNb0J2YXRqa2R4dFc2a2dMTGR3S2ZJQzR2WlEwd0NETDJmVlUxNi1fSHdHUW9DRzdTOU15d2R5Y0JCSEF2M1hKQWppbUVHOWNkNVo2VWVpYk5Md3l2b2JuVUtOd3o1dEtDT3p1UTZFZndMem8tN2ctRWxqZDloYksyVTJ2aWdCOGNCMExrbn…
DCTH - Delcath Systems Inc Stock Price and Quote - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9NVlltOUUtcWJuOWJKUlVtRHppN1RLOTItMklIemdPemUzM3N5YXpDMkItTzJqbGtEb0o0NzhjcmpSNXQweUE?oc=5" target="_blank">DCTH - Delcath Systems Inc Stock Price and Quote</a> <font co…
DCTH — Frequently Asked Questions
What is the current share price of Delcath Systems, Inc. (DCTH)?
As of 2026-09-07 16:24 PDT, Delcath Systems, Inc. (DCTH) trades at $16.48 on NasdaqCM. Its 52-week range is $8.19 to $17.36.
What is the market capitalisation of DCTH?
Delcath Systems, Inc. (DCTH) has a market capitalisation of $568.92M on NasdaqCM.
What is the return on equity (ROE) of DCTH?
DCTH has a return on equity (ROE) of 0.47%. Its return on capital employed (ROCE) is 0.59%.
Is DCTH a good stock to buy?
This page provides a data-driven analysis of Delcath Systems, Inc. (DCTH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.